| For: | Kuang YY, Xiong MQ, Cai JX. Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome. World J Clin Cases 2024; 12(22): 4992-4998 [PMID: 39109013 DOI: 10.12998/wjcc.v12.i22.4992] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v12/i22/4992.htm |
| Number | Citing Articles |
| 1 |
Helena Juricic, Massimiliano Cuccioloni, Laura Bonfili, Mauro Angeletti, Daniela Uberti, Anna Maria Eleuteri, Giulia Abate, Valentina Cecarini. Biochemical, Biological, and Clinical Properties of γ-Oryzanol. Antioxidants 2025; 14(9): 1099 doi: 10.3390/antiox14091099
|
| 2 |
Bi-Xing Liu. Impact of oryzanol plus femoston on efficacy, sleep quality, and quality of life in perimenopausal syndrome patients. American Journal of Translational Research 2025; 17(9): 7356 doi: 10.62347/CSXZ5615
|
| 3 |
Jochebed Hope H. Punzalan, Ross D. Vasquez. γ-Oryzanol and neuropsychiatric disorders: A scoping review of preclinical evidence, mechanistic insights, challenges, and translational relevance. Pharmacological Research - Natural Products 2026; 10: 100562 doi: 10.1016/j.prenap.2026.100562
|
